Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 142

1.

Fibroblast growth factor (FGF) and FGF receptor-mediated autocrine signaling in non-small-cell lung cancer cells.

Marek L, Ware KE, Fritzsche A, Hercule P, Helton WR, Smith JE, McDermott LA, Coldren CD, Nemenoff RA, Merrick DT, Helfrich BA, Bunn PA Jr, Heasley LE.

Mol Pharmacol. 2009 Jan;75(1):196-207. doi: 10.1124/mol.108.049544. Epub 2008 Oct 10.

2.

Fibroblast growth factor receptors are components of autocrine signaling networks in head and neck squamous cell carcinoma cells.

Marshall ME, Hinz TK, Kono SA, Singleton KR, Bichon B, Ware KE, Marek L, Frederick BA, Raben D, Heasley LE.

Clin Cancer Res. 2011 Aug 1;17(15):5016-25. doi: 10.1158/1078-0432.CCR-11-0050. Epub 2011 Jun 14.

3.

Rapidly acquired resistance to EGFR tyrosine kinase inhibitors in NSCLC cell lines through de-repression of FGFR2 and FGFR3 expression.

Ware KE, Marshall ME, Heasley LR, Marek L, Hinz TK, Hercule P, Helfrich BA, Doebele RC, Heasley LE.

PLoS One. 2010 Nov 29;5(11):e14117. doi: 10.1371/journal.pone.0014117.

4.

Activation of the FGF2-FGFR1 autocrine pathway: a novel mechanism of acquired resistance to gefitinib in NSCLC.

Terai H, Soejima K, Yasuda H, Nakayama S, Hamamoto J, Arai D, Ishioka K, Ohgino K, Ikemura S, Sato T, Yoda S, Satomi R, Naoki K, Betsuyaku T.

Mol Cancer Res. 2013 Jul;11(7):759-67. doi: 10.1158/1541-7786.MCR-12-0652. Epub 2013 Mar 27.

5.

Fibroblast Growth Factor Receptor 1 and Related Ligands in Small-Cell Lung Cancer.

Zhang L, Yu H, Badzio A, Boyle TA, Schildhaus HU, Lu X, Dziadziuszko R, Jassem J, Varella-Garcia M, Heasley LE, Kowalewski AA, Ellison K, Chen G, Zhou C, Hirsch FR.

J Thorac Oncol. 2015 Jul;10(7):1083-90. doi: 10.1097/JTO.0000000000000562.

6.

A mechanism of resistance to gefitinib mediated by cellular reprogramming and the acquisition of an FGF2-FGFR1 autocrine growth loop.

Ware KE, Hinz TK, Kleczko E, Singleton KR, Marek LA, Helfrich BA, Cummings CT, Graham DK, Astling D, Tan AC, Heasley LE.

Oncogenesis. 2013 Mar 25;2:e39. doi: 10.1038/oncsis.2013.4.

7.

Fibroblast growth factor receptor-mediated signals contribute to the malignant phenotype of non-small cell lung cancer cells: therapeutic implications and synergism with epidermal growth factor receptor inhibition.

Fischer H, Taylor N, Allerstorfer S, Grusch M, Sonvilla G, Holzmann K, Setinek U, Elbling L, Cantonati H, Grasl-Kraupp B, Gauglhofer C, Marian B, Micksche M, Berger W.

Mol Cancer Ther. 2008 Oct;7(10):3408-19. doi: 10.1158/1535-7163.MCT-08-0444.

8.
9.

Expression of fibroblast growth factor receptor genes in human hepatoma-derived cell lines.

Asada N, Tanaka Y, Hayashido Y, Toratani S, Kan M, Kitamoto M, Nakanishi T, Kajiyama G, Chayama K, Okamoto T.

In Vitro Cell Dev Biol Anim. 2003 Jul-Aug;39(7):321-8.

PMID:
14753849
10.

Evidence for a role of FGF-2 and FGF receptors in the proliferation of non-small cell lung cancer cells.

Berger W, Setinek U, Mohr T, Kindas-Mügge I, Vetterlein M, Dekan G, Eckersberger F, Caldas C, Micksche M.

Int J Cancer. 1999 Oct 29;83(3):415-23.

11.

Nonamplified FGFR1 is a growth driver in malignant pleural mesothelioma.

Marek LA, Hinz TK, von Mässenhausen A, Olszewski KA, Kleczko EK, Boehm D, Weiser-Evans MC, Nemenoff RA, Hoffmann H, Warth A, Gozgit JM, Perner S, Heasley LE.

Mol Cancer Res. 2014 Oct;12(10):1460-9. doi: 10.1158/1541-7786.MCR-14-0038. Epub 2014 Jun 25.

12.

Interaction between the estrogen receptor and fibroblast growth factor receptor pathways in non-small cell lung cancer.

Siegfried JM, Farooqui M, Rothenberger NJ, Dacic S, Stabile LP.

Oncotarget. 2017 Apr 11;8(15):24063-24076. doi: 10.18632/oncotarget.16030.

13.
14.

Targeting fibroblast growth factor receptors blocks PI3K/AKT signaling, induces apoptosis, and impairs mammary tumor outgrowth and metastasis.

Dey JH, Bianchi F, Voshol J, Bonenfant D, Oakeley EJ, Hynes NE.

Cancer Res. 2010 May 15;70(10):4151-62. doi: 10.1158/0008-5472.CAN-09-4479. Epub 2010 May 11.

15.

Down-regulation of (IIIb) and (IIIc) isoforms of fibroblast growth factor receptor 2 (FGFR2) is associated with malignant progression in human prostate.

Naimi B, Latil A, Fournier G, Mangin P, Cussenot O, Berthon P.

Prostate. 2002 Aug 1;52(3):245-52.

PMID:
12111699
16.

FGFR1 mRNA and protein expression, not gene copy number, predict FGFR TKI sensitivity across all lung cancer histologies.

Wynes MW, Hinz TK, Gao D, Martini M, Marek LA, Ware KE, Edwards MG, Böhm D, Perner S, Helfrich BA, Dziadziuszko R, Jassem J, Wojtylak S, Sejda A, Gozgit JM, Bunn PA Jr, Camidge DR, Tan AC, Hirsch FR, Heasley LE.

Clin Cancer Res. 2014 Jun 15;20(12):3299-309. doi: 10.1158/1078-0432.CCR-13-3060. Epub 2014 Apr 25.

17.

The fibroblast growth factor receptor signaling pathway as a mediator of intrinsic resistance to EGFR-specific tyrosine kinase inhibitors in non-small cell lung cancer.

Kono SA, Marshall ME, Ware KE, Heasley LE.

Drug Resist Updat. 2009 Aug-Oct;12(4-5):95-102. doi: 10.1016/j.drup.2009.05.001. Epub 2009 Jun 4. Review.

18.
19.

Fibroblast growth factor (FGF)-1, FGF2, FGF7 and FGF receptors are uniformly expressed in trophoblast giant cells during restricted trophoblast invasion in cows.

Pfarrer C, Weise S, Berisha B, Schams D, Leiser R, Hoffmann B, Schuler G.

Placenta. 2006 Jun-Jul;27(6-7):758-70. Epub 2005 Aug 29.

PMID:
16129484
20.

Expression of fibroblast growth factors (FGFs) and FGF receptors in human prostate.

Ittman M, Mansukhani A.

J Urol. 1997 Jan;157(1):351-6.

PMID:
8976296

Supplemental Content

Support Center